SCHEMBL17799666

SCHEMBL17799666

O=C(N[C@H]1CC[C@H]1c1ccc(Cl)cc1Cl)c1ccoc1Br

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TAS1R3 Q7RTX0 1/20 0.43
▸ TAS1R1 Q7RTX1 1/20 0.43
▸ TAS1R2 Q8TE23 1/20 0.43
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ F10 P00742 1/20 0.37
▸ SLC6A12 P48065 1/20 0.36
▸ HCRTR2 O43614 1/20 0.36
▸ DPP4 P27487 2/20 0.36
▸ HTR2A P28223 1/20 0.35
▸ HTR2C P28335 1/20 0.35
▸ HTR2B P41595 1/20 0.35
▸ RAB9A P51151 3/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CNR1 P21554 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16371739 0.86 LMNA (0.49) TAS1R3TAS1R1TAS1R2RAB9ANPC1
SCHEMBL17799712 0.86 LMNA (0.49) TAS1R3TAS1R1TAS1R2RAB9ANPC1
SCHEMBL17799653 0.83 AKT1 (0.39) TAS1R3TAS1R1TAS1R2
SCHEMBL17799710 0.81 NPC1 (0.47) TAS1R3TAS1R1TAS1R2MEN1KMT2A
SCHEMBL17799743 0.80 SLC6A12 (0.47) TAS1R3TAS1R1TAS1R2F10SLC6A12
SCHEMBL17799706 0.80 TAS1R3 (0.39) TAS1R3TAS1R1TAS1R2HCRTR2HTR2A
SCHEMBL17799763 0.80 RAB9A (0.44) TAS1R3TAS1R1TAS1R2MEN1KMT2A
SCHEMBL16220951 0.78 L3MBTL1 (0.57) TAS1R3TAS1R1TAS1R2MEN1KMT2A
SCHEMBL17799662 0.77 TAS1R3 (0.43) TAS1R3TAS1R1TAS1R2MEN1KMT2A
SCHEMBL17799764 0.77 TAS1R3 (0.52) TAS1R3TAS1R1TAS1R2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50724-E1 4-membered ring carboxamides used as nematicides SYNGENTA CROP PROTECTION AG (CH) 2026-01-06 — — US disclosed
EP-3019476-B1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 — — EP disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES TUBA3C, DDT, CYCS TAS1R3 3195/4885TAS1R1 3418/4885TAS1R2 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback